Johnson & Johnson (JNJ) : Cacti Asset Management reduced its stake in Johnson & Johnson by 0.92% during the most recent quarter end. The investment management company now holds a total of 259,955 shares of Johnson & Johnson which is valued at $28.4 Million after selling 2,405 shares in Johnson & Johnson according to a report filed by the company on Apr 1, 2016 with the SEC.Johnson & Johnson makes up approximately 3.05% of Cacti Asset Management’s portfolio.
Other Hedge Funds, Including , Renaissance Investment Group reduced its stake in JNJ by selling 202 shares or 0.98% in the most recent quarter. The Hedge Fund company now holds 20,471 shares of JNJ which is valued at $2.2 Million. Johnson & Johnson makes up approx 1.12% of Renaissance Investment Group’s portfolio.
On the company’s financial health, Johnson & Johnson reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jan 26, 2016. Analyst had a consensus of $1.42. The company had revenue of $17811.00 million for the quarter, compared to analysts expectations of $17856.07 million. The company’s revenue was down -2.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.27 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Johnson & Johnson was Upgraded by Goldman to ” Neutral” on Mar 14, 2016.
Johnson & Johnson closed down -0.13 points or -0.12% at $108.97 with 68,23,922 shares getting traded on Monday. Post opening the session at $109.15, the shares hit an intraday low of $108.65 and an intraday high of $109.62 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.